Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Proteomic Guided Precision Treatment of Renal Clear Cell Carcinoma
NCT06211790Phase 2Recruiting
- Sponsor
- Fudan University
- Start
- Jan 2024
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of anlotinib in clear cell renal cell carcinoma (ccRCC), sponsored by Fudan University. Started Jan 2024; status: recruiting.
02
Drugs
anlotinib
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on NCT06211790.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06211790.